AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2018
Mar 2, 2018
31868_dirs_2018-03-02_909c23c9-a4d9-4227-8a2b-0f26802572fe.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2018-02-28
Reporting Person: Stonehouse Jon P (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-02-28 | Common Stock | M | 56949 | $3.26 | Acquired | 698316 | Direct |
| 2018-02-28 | Common Stock | F | 43224 | $4.97 | Disposed | 655092 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-28 | Emp. Stock Option (Right to Buy) | $3.26 | M | 56949 | Disposed | 2018-03-14 | Common Stock (56949) | Direct |
Footnotes
F1: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20